115
Participants
Start Date
September 30, 2009
Primary Completion Date
September 30, 2011
Study Completion Date
September 30, 2011
treprostinil diethanolamine
sustained release tablet; BID dosing; up to 16 mg BID
The Hospital for Special Surgery, New York
North Shore - LIJ Health System, Lake Success
University of Pittsburgh, Pittsburgh
Georgetown University - Dept. of Medicine/Rheumatology, Washington D.C.
Johns Hopkins University - Division of Rheumatology, Baltimore
University of Toledo, Toledo
The Cleveland Clinic Foundation, Cleveland
University of Michigan - Scleroderma Program, Ann Arbor
Medical College of Wisconsin, Milwaukee
University of Minnesota, Minneapolis
Northwestern University - Feinberg School of Medicine, Chicago
University of Texas - Houston, Houston
Barbara Davis Centre, Aurora
University of Utah, Salt Lake City
Mayo Clinic Scottsdale, Scottsdale
Virginia Mason Medical, Seattle
University of Alabama - Birmingham - Arthritis Clinical Intervention Program, Birmingham
UCLA, Los Angeles
University of Connecticut Health Center, Farmington
Boston University School of Medicine, Boston
UMDNJ Clinical Research Center, New Brunswick
Medical University of South Carolina, Charleston
St Joseph's Health Care, London
Jewish General Hospital, Montreal
Royal Free Hospital - Center for Rheumatology, London
Salford Royal Hospital, Manchester
Lead Sponsor
United Therapeutics
INDUSTRY